THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS ...
ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ a Miroslav SOUČEK. THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. In 20th European meeting on Hypertension, Oslo, 18-21.6.2010. ISSN 1473-5598. 2010. |
Další formáty:
BibTeX
LaTeX
RIS
|
Základní údaje | |
---|---|
Originální název | THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. |
Název česky | Normalizovaný smoothness index a populační RDH index losartanu a telmisartanu u pacientů s čerstvě zjištěnou hypertenzí a metabolickým syndromem |
Název anglicky | THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. |
Autoři | ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ a Miroslav SOUČEK. |
Vydání | 20th European meeting on Hypertension, Oslo, 18-21.6.2010. 2010. |
Další údaje | |
---|---|
Originální jazyk | čeština |
Typ výsledku | Konferenční abstrakt |
Obor | 30201 Cardiac and Cardiovascular systems |
Stát vydavatele | Česká republika |
Utajení | není předmětem státního či obchodního tajemství |
WWW | URL |
Impakt faktor | Impact factor: 3.980 |
Organizační jednotka | Lékařská fakulta |
ISSN | 1473-5598 |
UT WoS | 000283023404270 |
Klíčová slova česky | smoothness index; RDH index; telmisartan; losartan |
Klíčová slova anglicky | smoothness index; RDH index; telmisartane; losartane |
Příznaky | Mezinárodní význam, Recenzováno |
Změnil | Změnil: MUDr. Ivan Řiháček, Ph.D., učo 2313. Změněno: 17. 1. 2011 13:02. |
Anotace |
---|
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane. |
Anotace anglicky |
---|
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane. |
Návaznosti | |
---|---|
MSM0021622402, záměr | Název: Časná diagnostika a léčba kardiovaskulárních chorob |
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Časná diagnostika a léčba kardiovaskulárních chorob |
VytisknoutZobrazeno: 29. 3. 2024 15:47